Found: 19
Select item for more details and to access through your institution.
CXCR1/2 inhibition enhances pancreatic islet survival after transplantation.
- Published in:
- Journal of Clinical Investigation, 2012, v. 122, n. 10, p. 1, doi. 10.1172/JCI63089
- By:
- Publication type:
- Article
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
- Published in:
- Breast Cancer Research & Treatment, 2021, v. 190, n. 2, p. 265, doi. 10.1007/s10549-021-06367-5
- By:
- Publication type:
- Article
Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241240972
- By:
- Publication type:
- Article
Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1840, doi. 10.1111/dom.14770
- By:
- Publication type:
- Article
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Armed antibodies for cancer treatment: a promising tool in a changing era.
- Published in:
- Cancer Immunology, Immunotherapy, 2015, v. 64, n. 1, p. 113, doi. 10.1007/s00262-014-1621-0
- By:
- Publication type:
- Article
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing.
- Published in:
- European Journal of Haematology, 2011, v. 86, n. 5, p. 385, doi. 10.1111/j.1600-0609.2011.01590.x
- By:
- Publication type:
- Article
Manipulating the Chemokine-Chemokine Receptor Network to Treat Cancer.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 12, p. 2392, doi. 10.1002/cncr.22706
- By:
- Publication type:
- Article
The CXCL8-CXCR1/2 Axis as a Therapeutic Target in Breast Cancer Stem-Like Cells.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00040
- By:
- Publication type:
- Article
Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
- Published in:
- Journal of Cellular Physiology, 2010, v. 223, n. 2, p. 384, doi. 10.1002/jcp.22045
- By:
- Publication type:
- Article
The therapeutic potential of an allosteric non‐competitive CXCR1/2 antagonist for diabetic nephropathy.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2023, v. 39, n. 7, p. 1, doi. 10.1002/dmrr.3694
- By:
- Publication type:
- Article
Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.
- Published in:
- International Journal of Biological Markers, 2015, v. 30, n. 3, p. e275, doi. 10.5301/jbm.5000149
- By:
- Publication type:
- Article
Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Safety and Pharmacokinetics of Escalating Doses of Human Recombinant Nerve Growth Factor Eye Drops in a Double-Masked, Randomized Clinical Trial.
- Published in:
- BioDrugs, 2014, v. 28, n. 3, p. 275, doi. 10.1007/s40259-013-0079-5
- By:
- Publication type:
- Article
Combined negative and positive selection of mobilized CD34<sup>+</sup> blood cells.
- Published in:
- British Journal of Haematology, 1996, v. 94, n. 4, p. 716, doi. 10.1046/j.1365-2141.1996.00725.x
- By:
- Publication type:
- Article
249-OR: A Randomized, Double-Blind Phase 2 Trial of the CXCR1/2 Inhibitor Ladarixin in Adult Patients with New-Onset Type 1 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-249-OR
- By:
- Publication type:
- Article
CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice.
- Published in:
- Diabetes, 2015, v. 64, n. 4, p. 1329, doi. 10.2337/db14-0443
- By:
- Publication type:
- Article